鼠神经生长因子联合依达拉奉治疗脑出血的临床效果及对神经功能的影响(1)
[摘要] 目的 探討鼠神经生长因子联合依达拉奉用于治疗脑出血的临床效果及对神经功能的影响。 方法 选择2014年1月～2016年10月延安大学附属医院收治的70例脑出血患者为研究对象，根据治疗方法的不同将其分为对照组和观察组，每组各35例。对照组患者在常规治疗的基础上给予依达拉奉注射液治疗，观察组在对照组治疗的基础上给予肌内注射鼠神经生长因子制剂。治疗前后，采用神经功能缺损评分(NIHSS)量表评估两组患者的神经功能缺损程度；采用酶联免疫吸附法测定血清神经元特异性烯醇化酶(NSE)、S100B蛋白水平及血清超敏C反应蛋白(hs-CRP)、白细胞介素8(IL-8)和肿瘤坏死因子α(TNF-α)水平。采用脑卒中影响量表(SIS)评价患者治疗后的生活质量。 结果 两组有效率(97.14%比74.29%)比较差异有统计学意义(P < 0.05)。治疗后两组hs-CRP、TNF-α、IL-8炎症因子水平及NSE、S100B水平均较治疗前明显降低，且观察组均低于对照组(P < 0.05)。治疗后，对照组及观察组NIHSS评分均较治疗前明显降低，且观察组明显低于对照组(P < 0.05)。治疗后SIS量表各项评比较，观察组力气、手功能、日常生活活动能力、移动能力、交流能力、记忆与思维、社会参与评分明显高于对照组(P < 0.05)，两组情绪评分比较差异无统计学意义(P > 0.05)。 结论 鼠神经生长因子联合依达拉奉治疗脑出血患者效果显著，可明显降低患者炎症因子水平，改善神经功能，提高患者的生活质量，值得在临床上推广应用。
[关键词] 鼠神经生长因子；依达拉奉；脑出血；神经功能
[中图分类号] R743.3 [文献标识码] A [文章编号] 1673-7210(2017)02(b)-0145-04
[Abstract] Objective To study the clinical effect of mouse nerve growth factor combined with Edaravone in the treatment of cerebral hemorrhage and the effect on neural function. Methods Seventy cases of patients with cerebral hemorrhage admitted to the Affiliated Hospital of Yan'an University from January 2014 to October 2016 were selected as the research objects， according to the treatment methods， they were divided into control group and observation group， with 35 cases in each group. The two groups were given the routine therapy， and the control group was treated with Edaravone， on the basis of which， the observation group was given intramuscular mouse nerve growth factor in addition. Before and after treatment， national institute of health stroke scale (NIHSS) was used for the assessment of the nerve function defect degree of patients in the two groups； the levels of serum NSE， called S100B protein and serum high-sensitivity C-reactive protein (hs-CRP)， interleukin-8 (IL-8) and tumor necrosis factor α (TNF-α) were detected by enzyme linked immune sorbent assay. Life quality of patients was evaluated by the stroke impact scale (SIS) after treatment. Results There was statistically significant difference in the efficient between the two groups (97.14% vs 97.14%， P < 0.05). After treatment， the levels of hs-CRP， IL-8， TNF-α and NSE， called S100B levels in the two groups were significantly lower than those before treatment， and the observation group was lower than that of the control group， the differences were statistically significant (P < 0.05). After treatment， the NIHSS scores of the two groups were significantly lower than those before treatment， and the observation group was significantly lower than the control group， the differences were statistically significant (P < 0.05). In SIS scale， the scores of strength， hand function， activities of daily living， mobile power， communication， memory and thinking， social participation score of patients in the observation group after treatment were significantly higher than those of the control group， the differences were statistically significant (P < 0.05)， the scores of mood between the two groups had no statistically significant difference (P > 0.05). Conclusion Mouse nerve growth factor combined with Edaravone in the treatment of patients with cerebral hemorrhage has a marked effect， which can significantly lower the levels of inflammatory factor， improve the neural function， enhance the quality of life， it is worthy of popularization and application in clinic., 百拇医药(吴瑞 董治燕 李海军)
[关键词] 鼠神经生长因子；依达拉奉；脑出血；神经功能
[中图分类号] R743.3 [文献标识码] A [文章编号] 1673-7210(2017)02(b)-0145-04
[Abstract] Objective To study the clinical effect of mouse nerve growth factor combined with Edaravone in the treatment of cerebral hemorrhage and the effect on neural function. Methods Seventy cases of patients with cerebral hemorrhage admitted to the Affiliated Hospital of Yan'an University from January 2014 to October 2016 were selected as the research objects， according to the treatment methods， they were divided into control group and observation group， with 35 cases in each group. The two groups were given the routine therapy， and the control group was treated with Edaravone， on the basis of which， the observation group was given intramuscular mouse nerve growth factor in addition. Before and after treatment， national institute of health stroke scale (NIHSS) was used for the assessment of the nerve function defect degree of patients in the two groups； the levels of serum NSE， called S100B protein and serum high-sensitivity C-reactive protein (hs-CRP)， interleukin-8 (IL-8) and tumor necrosis factor α (TNF-α) were detected by enzyme linked immune sorbent assay. Life quality of patients was evaluated by the stroke impact scale (SIS) after treatment. Results There was statistically significant difference in the efficient between the two groups (97.14% vs 97.14%， P < 0.05). After treatment， the levels of hs-CRP， IL-8， TNF-α and NSE， called S100B levels in the two groups were significantly lower than those before treatment， and the observation group was lower than that of the control group， the differences were statistically significant (P < 0.05). After treatment， the NIHSS scores of the two groups were significantly lower than those before treatment， and the observation group was significantly lower than the control group， the differences were statistically significant (P < 0.05). In SIS scale， the scores of strength， hand function， activities of daily living， mobile power， communication， memory and thinking， social participation score of patients in the observation group after treatment were significantly higher than those of the control group， the differences were statistically significant (P < 0.05)， the scores of mood between the two groups had no statistically significant difference (P > 0.05). Conclusion Mouse nerve growth factor combined with Edaravone in the treatment of patients with cerebral hemorrhage has a marked effect， which can significantly lower the levels of inflammatory factor， improve the neural function， enhance the quality of life， it is worthy of popularization and application in clinic., 百拇医药(吴瑞 董治燕 李海军)